OmniAb Projects 2026 Revenue Between $35M and $39M Driven by Strategic Partnerships
OmniAb (OABI) has provided a revenue outlook for 2026, forecasting between $35 million and $39 million. This growth trajectory is supported by the company's existing partnership with Eli Lilly and its strategic 'xPloration' initiative, which aims to double program progression. During the Q3 earnings call, CEO Matthew Foehr highlighted that the company's differentiated technology platforms are successfully driving increased partnerships and advancing therapeutic programs. The management team views these technological advantages as key drivers for long-term revenue scaling.
